NRG-GU015, the "ARCHER" Study for Muscle Invasive Bladder Cancer

Our co-hosts welcome Dr. Scott Delacroix and Dr. Himanshu Nagar to discuss bladder cancer, bladder preservation, and the newly activated NRG-GU015 (ARCHER) clinical trial. In this episode, the experts explore who may benefit from bladder-sparing chemoradiation, dispel common misconceptions about organ preservation, and explain how GU015 is evaluating a shorter, adaptive radiation treatment approach that could make curative therapy more accessible for patients with muscle-invasive bladder cancer. They also discuss the importance of multidisciplinary care, patient-centered decision-making, and how innovations in radiation therapy and systemic treatments are shaping the future of bladder cancer care. Whether you're a clinician, researcher, or simply interested in advances in oncology, this episode offers valuable insights into a trial designed to improve both outcomes and quality of life for patients.